Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli Lilly, the manufacturer of Mounjaro, eating smaller, more frequent meals, ...

It's also working on another, even more powerful weight-loss shot. While Ozempic mimics one hunger-relieving hormone, and Mounjaro mimics two, Eli Lilly is working on what's called a "triple ...

Patrik Jonsson is an executive vice president at Eli Lilly ... Jonsson has run Lilly Diabetes and Obesity, which means he oversees everything from insulin shots to the newer, high-demand drugs now ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly(NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by far ...

This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...

As evidence has mounted that new diabetes and weight loss drugs can provide ... Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound. “We’re saying there ...